Ustekinumab in adolescent patients age 12 to 17Â years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

Article ID	Journal	Published Year	Pages	File Type
6071122	Journal of the American Academy of Dermatology	2015	10 Pages	PDF

Abstract

In this patient population (12-17Â years), the standard ustekinumab dose provided responseÂ comparable to that in adults with no unexpected AEs through 1Â year.

Keywords

SAE PASI 90 standard dose PASI 75 ustekinumab CDLQI PGA HRQOL HSD Physician's Global Assessment Pediatric PASI Biologic Systemic therapy Children's Dermatology Life Quality Index adverse event Serious adverse event psoriasis area and severity index Adolescent Psoriasis Children Health-related quality of life

Related Topics

Health Sciences Medicine and Dentistry Dermatology

Preview

Ustekinumab in adolescent patients age 12 to 17Â years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

Authors

Ian MD, FRCPC, Colleen PhD, Ming-Chun PhD, Shu PhD, Yaowei PhD, Lawrence F. MD, Peter H. MD, Alan MD, Amy S. MS, MD, Alain MD, Sandra MD, Philippe MD, MSCE, Bruce MD, PhD,